The tumor-promoting function of CRY1 has been further suggested in a recent study showing that CRY1 enhances p53 tumor suppressor degradation via p53 binding to its ubiquitin E3 ligase MDM2 proto‐oncogene in bladder cancer cells, thereby increasing anticancer drug sensitivity50. This evidence concerns the gene CRY1 and urinary bladder carcinoma.